PeptideGLP-1GLP-1 Agonist

Cagrilintide

Amylin analog (NOT a GLP-1)

Typical dose

0.3–2.4 mg weekly

once weekly · SubQ · often stacked w/ semaglutide

Half-life

~7 days

What is Cagrilintide?

Long-acting amylin analog used for appetite/weight management, often combined with semaglutide (CagriSema).

How Cagrilintide works

Long-acting amylin analog — mimics the meal-satiety hormone amylin, acting on the brain (area postrema/hypothalamus) to reduce appetite and slow gastric emptying. Different receptor system than GLP-1.

Benefits & uses

Appetite reduction / satiety (amylin pathway — distinct from GLP-1)
Slows gastric emptying
Complements GLP-1 drugs (basis of CagriSema)
Weight loss (~8–10% monotherapy)

Common uses: Fat loss / obesity, often stacked with a GLP-1 for additive effect.

Cagrilintide dosage

Typical dose: Typical: start 0.3 mg/week SubQ, titrate up toward 2.4 mg/week over several weeks. Often stacked with semaglutide.

Cagrilintide half-life

~7 days (amylin analog)

Cagrilintide side effects

Nausea
Vomiting
Diarrhea/constipation
Injection-site reactions
GI events reported in 41–63% at higher doses

Warnings & monitoring

Titrate slowly to limit GI effects
Injection-site reactions noted
Investigational — no approved dosing schedule; use under medical/clinical guidance
Not for pregnancy

Preparation & storage

Preparation: Mix a 5 mg vial with 2 mL bac water → 2,500 mcg/mL. A 0.3 mg dose = 0.12 mL = 12 units. Titrate up over several weeks.
Reconstitution: Reconstitute a 5 mg vial with 2 mL BAC water → 2.5 mg/mL. A 0.3 mg dose = 0.12 mL = 12 units on a U-100 syringe.

Track Cagrilintide in Protokol.

Log doses, model half-lives, check interactions, and line it all up against your bloodwork. Free on iPhone and Android.